2025
- 2025.5.13PRBrightPath Presented Manufacturing Process Development Updates for iPS Cell-derived BCMA CAR-iNKT Cells (BP2202) at ASGCT 2025(130KB)
- 2025.5.9IRFinancial Results for the Fiscal Year ended March 31, 2025 [Japanese GAAP] (non-consolidated)(462KB)
- 2025.5.8PRBrightPath to Present the Data of Manufacturing Process of iPS Cell-derived BCMA CAR-iNKT Cells (BP2202) at ASGCT 2025(151KB)
- 2025.4.29PRBrightPath Presented the Preclinical Data of iPSC-derived HER2 CAR-iNKT cells at AACR 2025(83KB)
- 2025.3.27PRBrightPath to Present the Preclinical Data of iPSC-derived HER2 CAR-iNKT cells at AACR 2025(106KB)
- 2025.2.14IRFinancial Results for the Nine Months ended December 31, 2024 [Japanese GAAP] (non-consolidated)(311KB)
- 2025.5.13PRBrightPath Presented Manufacturing Process Development Updates for iPS Cell-derived BCMA CAR-iNKT Cells (BP2202) at ASGCT 2025(130KB)
- 2025.5.8PRBrightPath to Present the Data of Manufacturing Process of iPS Cell-derived BCMA CAR-iNKT Cells (BP2202) at ASGCT 2025(151KB)
- 2025.4.29PRBrightPath Presented the Preclinical Data of iPSC-derived HER2 CAR-iNKT cells at AACR 2025(83KB)
- 2025.3.27PRBrightPath to Present the Preclinical Data of iPSC-derived HER2 CAR-iNKT cells at AACR 2025(106KB)